Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04228965 · ClinicalTrials.gov registry record · Phase 4
Cannabis and Tobacco Co-use Study
A Phase 4 study, sponsored by Medical University of South Carolina.
- Completed
- Registry status
- Phase 4
- Development phase
- 181
- Enrollment target
NCT04228965: Completed Phase 4 study, sponsored by Medical University of South Carolina.
NCT04228965 is a Phase 4 study that has completed, run by Medical University of South Carolina. The registered enrollment target is 181 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (65% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04228965, a Phase 4 study, has completed, sponsored by Medical University of South Carolina.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 181 participants
- Enrollment target
Study Summary
The purpose of this study is to better understand tobacco outcomes using a well-known stop smoking medication, varenicline, and financial incentives with tobacco users. The investigators are also interested in how cannabis/marijuana and tobacco interact during a tobacco quit attempt. All participants will receive tobacco cessation treatment (varenicline) for 12 weeks. This study will recruit adult tobacco users (ages 18-40) who are motivated to quit smoking cigarettes.
Primary Outcome
7-day point prevalence abstinence from tobacco at the end of treatment (Week 12) will be assessed via biochemical verification (urinary cotinine; ng/ml) and will be compared between cannabis co-users and tobacco only controls.
Interventions
- DRUG Varenicline
- BEHAVIORAL Contingency Management
- BEHAVIORAL Counseling
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 181 participants |
| Start Date | 2020-01-28 |
| Est. Completion | 2024-09-13 |
| Phase | Phase 4 |
What the finished NCT04228965 record still lists
NCT04228965 is an interventional study that assigns participants to a tested intervention. The registered 181 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (65% lower).
The record links to 0 conditions, and to 3 interventions - of which Varenicline is the first listed.
NCT04228965 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04228965 about?
NCT04228965 is a clinical study titled "Cannabis and Tobacco Co-use Study". The purpose of this study is to better understand tobacco outcomes using a well-known stop smoking medication, varenicline, and financial incentives with tobacco users. The investigators are also interested in how cannabis/marijuana and tobacco interact during a tobacco quit attempt. All participant...
What is the current status of trial NCT04228965?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 181 participants. The study started on 2020-01-28. Estimated completion is 2024-09-13.
What interventions are being tested in trial NCT04228965?
The interventions under investigation include: Varenicline (DRUG), Contingency Management (BEHAVIORAL), Counseling (BEHAVIORAL).
Who is sponsoring clinical trial NCT04228965?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04228965's enrollment target sits among peer trials
181 464th of 2000 higher than 1,535 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04578392 · 181 participants · NA
MeSenteric SpAring Versus High Ligation Ileocolic Resection for the Prevention of REcurrent Crohn's DiseaSe (SPARES)
- NCT05597891 · 181 participants · NA
Endovascular Engineering ENGULF Study
- NCT03897998 · 182 participants · Phase 2
Neural Correlates of Hypoalgesia Driven by Observation
- NCT04300556 · 182 participants · Phase 1
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI